

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q83226

Noriko SHIMOZONO , et al.

Appln. No.: 10/506,907

Group Art Unit: not yet assigned

Confirmation No.: Not yet assigned.

Filed: September 07, 2004

For: SUBSTITUTED ISOXAZOLE ALKYLAMINE DERIVATIVE AND
AGRIHORTICULTURAL FUNGICIDE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/506,907

Attorney Docket No. Q83226

Also, Applicants submit herewith a copy of the Notification of Transmittal of Copies of Translation of the International Preliminary Examination Report (PCT Article 36 and Rule 70) Communication received from the International Bureau.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant submits the following explanations:

The disclosure on page 1 of the present specification for JP 9-509951 and the submission of an English language abstract for corresponding published patent application WO 95/24397 constitutes a concise statement of relevance of WO 95/24397.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.


INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/506,907

Attorney Docket No. Q83226

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Bruce E. Kramer
Registration No. 33,725

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: December 8, 2004

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/506,907
Confirmation Number	Not yet assigned.
Filing Date	September 07, 2004
First Named Inventor	Noriko SHIMOZONO
Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	Q83226

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 5,859,257	A	01-12-1999	John T. Talley
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	95/24397	A1	09-14-1995	HOECHST AKTIENGESELLSCHAFT	ABSTRACT
		WO	98/28282	A2	07-02-1998	THE DU PONT MERCK PHARMACEUTICAL COMPANY	
		GB	1,067,203		05-03-1967	HIDEO KANO, IKUO ADACHI, RYONOSUKE KIDO and KATSUMI KIROSE	
		EP	0 277 791	A2	08-10-88	FARMITALIA CARLO ERBA S.R.L.	ABSTRACT
		WO	96/38426	A1	12-05-1996	THE DU PONT MERCK PHARMACEUTICAL COMPANY	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.